Conference Coverage

Bleeding disorder diagnoses delayed by years in girls and women


 

FROM EAHAD 2021

Barriers to diagnosis

Patients and families have reported difficulty distinguishing normal bleeding from abnormal symptoms, and girls may be reluctant to discuss their symptoms with their family or peers. In addition, primary care practitioners may not recognize the severity of the symptoms and therefore may not refer patients to hematologists for further workup.

These findings emphasize the need for improved tools to help patients differentiate between normal and abnormal bleeding, using symptom recognition–based language tools that can lead to early testing and application of accurate diagnostic tools, she said.

Standardization of definitions can help to improve screening and diagnosis, Dr. D’Oiron said, pointing to a recent study in Blood Advances proposing definitions for future research in von Willebrand disease.

For example, the authors of that study proposed a definition of heavy menstrual bleeding to include any of the following:

  • Bleeding lasting 8 or more days
  • Bleeding that consistently soaks through one or more sanitary protections every 2 hours on multiple days
  • Requires use of more than one sanitary protection item at a time
  • Requires changing sanitary protection during the night
  • Is associated with repeat passing of blood clots
  • Has a Pictorial Blood Assessment Chart score greater than 100.

Problem and solutions

Answering the question posed in the title of her talk, Dr. D’Oiron said: “Yes, we do have a problem with the diagnosis of bleeding disorders in women and girls, but we also have solutions.”

The solutions include family and patient outreach efforts; communication to improve awareness; inclusion of general practitioners in the circle of care; and early screening, diagnosis, and treatment.

A bleeding disorders specialist who was not involved in the study said that Dr. D’Oiron’s report closely reflects what she sees in the clinic.

“I do pediatrics, and usually what happens is that I see a teenager with heavy menstrual bleeding and we take her history, and we find out that Mom and multiple female family members have had horrible menstrual bleeding, possibly many of whom have had hysterectomies for it, and then diagnosing the parents and other family members after diagnosing the girl that we’re seeing” said Veronica H. Flood, MD, from the Medical College of Wisconsin, Milwaukee.

“It is unfortunately a very real thing,” she added.

Reasons for the delay likely include lack of awareness of bleeding disorders.

“If you present to a hematologist, we think about bleeding disorders, but if you present to a primary care physician, they don’t always have that on their radar,” she said.

Additionally, a girl from a family with a history of heavy menstrual bleeding may just assume that what she is experiencing is “normal,” despite the serious affect it has on her quality of life, Dr. Flood said.

Dr. D’Oiron’s research is supported by her institution, the French Hemophilia Association, FranceCoag and Mhemon, the European Hemophilia Consortium, and the World Federation of Hemophilia. She reported advisory board or invited speaker activities for multiple companies. Dr. Flood reported having no conflicts of interest to disclose.

Pages

Recommended Reading

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction
MDedge Internal Medicine
Cost is the main hurdle to broad use of caplacizumab for TTP
MDedge Internal Medicine
Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A
MDedge Internal Medicine
A 4-point thrombocytopenia score was found able to rule out suspected HIT
MDedge Internal Medicine
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
MDedge Internal Medicine
Von Willebrand disease guidelines address women’s bleeding concerns
MDedge Internal Medicine
Doctors search for missing link between COVID-19 and ITP
MDedge Internal Medicine
Immunoabsorption shows promise as an adjunct treatment for high-risk acquired hemophilia
MDedge Internal Medicine
Factor VIII concentrate is here to stay in hemophilia A
MDedge Internal Medicine
Safety profiles of hemophilia agents vary widely
MDedge Internal Medicine